Related Experiment Video

Updated: May 25, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity

Joyce James1, Bruce Ruggeri, Robert C Armstrong

  • 1Ambit Biosciences Corporation, San Diego, CA 92121, USA. jjames@ambitbio.com

Molecular Cancer Therapeutics
|February 10, 2012
PubMed

Insights

CEP-32496 is a novel BRAF inhibitor demonstrating potent activity against BRAF(V600E) mutations common in cancers like melanoma and colorectal cancer. This orally bioavailable drug shows efficacy in preclinical models with a favorable safety profile, warranting clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF gene mutations, particularly V600E, are prevalent in various cancers, including melanoma, thyroid, and colorectal cancers.
  • Activating BRAF mutations confer cellular transforming and immortalization potential, driving cancer progression.
  • Targeting BRAF is a key strategy in cancer therapy.

Purpose of the Study:

  • To evaluate the preclinical efficacy and safety of CEP-32496, a novel BRAF inhibitor.
  • To assess CEP-32496's inhibitory activity against mutated BRAF(V600E) and its downstream signaling pathways.
  • To determine CEP-32496's oral bioavailability, pharmacodynamic effects, and antitumor activity in preclinical cancer models.

Main Methods:

  • In vitro kinase inhibition assays using mutated BRAF(V600E) and cell lines (A375, Colo-205).
  • Assessment of cellular cytotoxicity against BRAF(V600E) versus wild-type cells.
  • Evaluation of oral bioavailability, pharmacodynamics (pMEK, pERK inhibition), and antitumor efficacy in BRAF(V600E) xenograft models (melanoma, colon carcinoma).
  • Toxicology studies in rodents and primates to assess safety and side effect profiles.

Main Results:

  • CEP-32496 demonstrated potent inhibition of BRAF(V600E) (K(d) = 14 nmol/L) and downstream signaling (pMEK IC(50) = 78 nmol/L in A375, 60 nmol/L in Colo-205).
  • Selective cytotoxicity for BRAF(V600E) cells over wild-type cells was observed.
  • High oral bioavailability (>95%) and dose-dependent inhibition of pMEK/pERK in vivo were confirmed.
  • Sustained tumor stasis and regressions were achieved in xenograft models without significant adverse effects or epithelial hyperplasia.

Conclusions:

  • CEP-32496 is a potent and selective BRAF(V600E) inhibitor with favorable oral bioavailability and preclinical antitumor activity.
  • The drug exhibits a promising safety profile, with minimal adverse effects observed in preclinical studies.
  • CEP-32496 represents a promising therapeutic candidate for BRAF(V600E)-mutated cancers, currently in clinical development.

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...